BioSpace News Archive

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 29, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 5 individuals hired by Sarepta in February 2024.

RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 34th Annual Oppenheimer Healthcare Conference.

Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share. All of the shares to be sold in the offering are to be sold by Celldex.

Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today announced the pricing of an underwritten public offering of 13,400,000 shares of its common stock at a public offering price of $3.00 per share.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen’s 44th Annual Health Care Conference.

Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ:SYRE), a biotechnology company advancing a pipeline of investigational antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (“IBD”), today announced its fourth quarter and full year 2023 financial results and provided program and corporate updates.

BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2023, and introduces 2024 revenue guidance.

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a review of recent accomplishments and anticipated upcoming developments.

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fourth quarter and twelve months ended December 31, 2023.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”) today announced that it will report financial results for the fourth quarter and fiscal year ended December 31, 2023 on March 7, 2024.